Cargando…

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second-generation CAR that is outfitted with an ectodoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chekol Abebe, Endeshaw, Yibeltal Shiferaw, Mestet, Tadele Admasu, Fitalew, Asmamaw Dejenie, Tadesse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479060/ https://www.ncbi.nlm.nih.gov/pubmed/36119032 http://dx.doi.org/10.3389/fimmu.2022.991092

Ejemplares similares

The newly emerged COVID-19 disease: a systemic review
por: Abebe, Endeshaw Chekol, et al.
Publicado: (2020)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study
por: Admasu, Fitalew Tadele, et al.
Publicado: (2023)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
por: Abebe, Endeshaw Chekol, et al.
Publicado: (2023)

Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

Impact of objectively-measured sleep duration on cardiometabolic health: A systematic review of recent evidence
por: Dejenie, Tadesse Asmamaw, et al.
Publicado: (2022)

Prevalence and determinants of anemia among children aged from 6 to 59 months in Liberia: a multilevel analysis of the 2019/20 Liberia demographic and health survey data
por: Adugna, Dagnew Getnet, et al.
Publicado: (2023)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Gay, F, et al.
Publicado: (2022)

Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor
por: Abebe, Endeshaw Chekol, et al.
Publicado: (2022)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

The magnitude of neonatal asphyxia and its associated factors among newborns in public hospitals of North Gondar Zone, Northwest Ethiopia: A cross-sectional study
por: Admasu, Fitalew Tadele, et al.
Publicado: (2022)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2021)

Evaluation of liver function biomarkers, blood pressure, and anthropometric parameters among chronic kidney disease patients: Laboratory-based cross-sectional study in Northwest Ethiopia
por: Agidew, Melaku Mekonnen, et al.
Publicado: (2023)

The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications
por: Abebe, Endeshaw Chekol, et al.
Publicado: (2022)

Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2021)

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
por: Delforge, Michel, et al.
Publicado: (2022)

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Prevalence and Associated Factors of Human Immune Deficiency Virus and Tuberculosis Co-Infection in Patients Attending Kolla Diba Health Center, Dembia District, Northwest Ethiopia
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2021)

Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
por: Tiruneh G/Medhin, Markeshaw, et al.
Publicado: (2021)

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
por: Weisel, Katja, et al.
Publicado: (2021)

Prevalence and predictors of dyslipidemia among HAART treated and HAART naive HIV positive clients attending Debre Tabor Hospital, Debre Tabor, Ethiopia
por: Tilahun, Anemut, et al.
Publicado: (2022)

Undernutrition and associated factors among internally displaced lactating mothers in Sekota camps, northern Ethiopia: A cross-sectional study
por: Mengstie, Misganaw Asmamaw, et al.
Publicado: (2023)

The Role of Regulatory B Cells in Health and Diseases: A Systemic Review
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2021)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
por: Weisel, K., et al.
Publicado: (2022)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT
por: Decaux, O., et al.
Publicado: (2022)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h96gnvib7k89asgtqak7c7n4mj